News|Articles|November 18, 2026

Galinpepimut-S Cuts Risk of Death by 41% in Phase 3 REGAL Trial

Listen
0:00 / 0:00

Key Takeaways

  • Median OS improved by 9.3 months with GPS versus heterogeneous investigator-selected care, meeting the primary endpoint after 80 deaths (HR 0.59; two-sided P=.035).
  • Enrollment focused on a high-unmet-need subset: post-relapse AML in second or later CR/CRp after ≥2L salvage, ineligible for or unable to undergo allogeneic transplant.
SHOW MORE

In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.

Galinpepimut-S (GPS), an investigational therapeutic vaccine, achieved a median overall survival (OS) of 24.0 months vs 14.7 months with investigator-selected care in patients with acute myeloid leukemia (AML). The phase 3 REGAL trial (NCT04229979) met its primary end point (hazard ratio [HR], 0.59; 2-sided P = .035), with a 41% lower hazard of death in the GPS group.¹

REGAL focused on a group with few maintenance options: patients whose AML had relapsed, who achieved another remission with salvage therapy, and who were ineligible for or unable to undergo allogeneic hematopoietic stem cell transplantation. The study evaluated whether starting GPS in that remission could extend survival.¹˒²

REGAL Evaluates Maintenance After AML Relapse

The global, open-label trial randomly assigned 126 patients 1:1 to GPS monotherapy or investigator-selected care. Eligible patients had achieved a second or later complete remission, including complete remission with insufficient platelet recovery, following second-line or later salvage therapy. Control options included observation or treatment with a hypomethylating agent, venetoclax, low-dose cytarabine, or combinations of those agents.¹

Investigators measured OS from study entry and conducted the primary analysis after the prespecified 80 deaths. The reported medians were 9.3 months apart. The HR compares GPS with the control arm as a whole.

The topline release did not report the HR confidence interval or give a breakdown of the number of patients who received each control regimen. Those details would help clinicians assess the precision of the survival estimate and how closely the control arm reflects their practice.¹

SELLAS reported that treatment-related adverse events with GPS were predominantly grade 1 or 2, with local injection-site reactions occurring most often. The company identified no new safety signals. Few patients went on to receive a transplant during the study, and those patients were evenly distributed between the groups, according to SELLAS. The topline release did not include detailed rates of higher-grade adverse events or treatment discontinuations.¹

A Vaccine Designed to Target Residual Leukemia

Developed at Memorial Sloan Kettering Cancer Center, GPS is a peptide-based therapeutic vaccine directed against Wilms tumor 1 (WT1), a protein expressed by AML cells. The vaccine is designed to stimulate a T-cell response against residual leukemia cells that express WT1. GPS uses a standardized formulation, so each dose can be produced without designing a vaccine from an individual patient’s tumor sample.¹˒²

An earlier phase 2 study evaluated the vaccine in adults in first complete remission.³ REGAL moved the investigation into a later-remission population and used a randomized comparison to evaluate survival.

For pharmacists counseling patients about maintenance, the remission setting determines which evidence applies. Oral azacitidine (Onureg; Bristol-Myers Squibb), for example, is indicated for continued treatment after a first complete remission or first complete remission with incomplete blood count recovery following intensive induction chemotherapy in adults who cannot complete intensive curative therapy. Oral azacitidine has a distinct indication and dosing regimen from intravenous or subcutaneous azacitidine and should not be substituted for those formulations.⁴

What the Full Results Could Clarify

The company has yet to report leukemia-free survival or detailed measurable residual disease findings. Those analyses could help clarify whether the OS result was accompanied by a longer time without leukemia or changes in detectable disease. Injection-site reaction rates by treatment arm would give pharmacists more specific information for counseling. Rates of treatment interruption and discontinuation would show how often adverse events affected patients’ ability to stay on maintenance therapy.¹

SELLAS said it plans to present the full results at a future medical meeting and submit them for peer-reviewed publication. The company plans to meet with the FDA to discuss its filing strategy and is preparing for a potential biologics license application submission in the first half of 2027. Galinpepimut-S remains investigational.¹

REFERENCES
  1. SELLAS Life Sciences Group Inc. SELLAS Life Sciences announces positive pivotal phase 3 REGAL trial data showing immunotherapeutic cancer vaccine, galinpepimut-S (GPS), demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with acute myeloid leukemia. News release. November 17, 2026. Accessed November 18, 2026. default.aspx
  2. Memorial Sloan Kettering Cancer Center. Investigational peptide vaccine demonstrates survival benefit in people with acute myeloid leukemia. November 17, 2026. Accessed November 18, 2026. https://www.mskcc.org/news-releases/investigational-peptide-vaccine-demonstrates-survival-benefit-in-people-with-acute-myeloid-leukemia
  3. Maslak PG, Dao T, Bernal Y, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224-234. doi:10.1182/bloodadvances.2017014175
  4. Onureg. Prescribing information. Bristol-Myers Squibb Company; 2026. Accessed November 18, 2026.pi_onureg.pdf

Related to this article